BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E27.39 EPS (ttm)2.82 Insider Own0.10% Shs Outstand2.15B Perf Week-1.39%
Market Cap163.72B Forward P/E9.47 EPS next Y8.15 Insider Trans-8.02% Shs Float2.13B Perf Month1.42%
Income6.25B PEG6.18 EPS next Q1.90 Inst Own79.20% Short Float1.66% Perf Quarter13.54%
Sales46.96B P/S3.49 EPS this Y178.00% Inst Trans2.16% Short Ratio2.29 Perf Half Y35.22%
Book/sh14.72 P/B5.24 EPS next Y7.38% ROA5.80% Target Price79.40 Perf Year15.53%
Cash/sh7.05 P/C10.94 EPS next 5Y4.43% ROE17.70% 52W Range53.22 - 78.46 Perf YTD23.70%
Dividend2.16 P/FCF15.35 EPS past 5Y3.30% ROI9.40% 52W High-1.34% Beta0.46
Dividend %2.80% Quick Ratio1.20 Sales past 5Y19.00% Gross Margin79.60% 52W Low45.45% ATR1.54
Employees32200 Current Ratio1.30 Sales Q/Q5.20% Oper. Margin19.00% RSI (14)58.02 Volatility1.81% 2.01%
OptionableYes Debt/Eq1.42 EPS Q/Q-33.80% Profit Margin13.30% Rel Volume0.44 Prev Close77.13
ShortableYes LT Debt/Eq1.19 EarningsApr 29 BMO Payout70.70% Avg Volume15.42M Price77.41
Recom2.20 SMA201.42% SMA503.08% SMA20017.92% Volume521,508 Change0.36%
Apr-06-22Resumed Morgan Stanley Underweight $64
Dec-17-21Initiated Goldman Buy $72
Dec-09-21Resumed Wells Fargo Equal Weight $58
Nov-19-21Initiated BMO Capital Markets Outperform $72
Nov-01-21Downgrade Argus Buy → Hold
Jul-27-21Resumed Truist Buy $74
Apr-30-21Downgrade Morgan Stanley Overweight → Equal-Weight $70 → $62
Apr-13-21Upgrade Truist Hold → Buy
Nov-16-20Upgrade Societe Generale Hold → Buy $76
Nov-10-20Resumed Bernstein Mkt Perform
Nov-06-20Downgrade Gabelli & Co Buy → Hold
Oct-19-20Upgrade Guggenheim Neutral → Buy $70
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
May-24-22 12:21PM  
07:44AM  
May-23-22 10:32AM  
10:14AM  
09:33AM  
May-20-22 02:17PM  
May-19-22 10:08AM  
06:59AM  
May-18-22 11:41AM  
May-17-22 02:06PM  
11:33AM  
May-16-22 05:53PM  
10:16AM  
09:56AM  
06:59AM  
May-13-22 02:29PM  
06:59AM  
May-12-22 03:13PM  
09:48AM  
06:59AM  
May-11-22 06:26PM  
09:06AM  
May-07-22 11:07AM  
May-05-22 04:35PM  
10:02AM  
May-04-22 02:21PM  
01:39PM  
06:59AM  
May-02-22 10:44AM  
Apr-30-22 10:28AM  
Apr-29-22 04:04PM  
02:00PM  
12:29PM  
11:19AM  
11:12AM  
10:43AM  
10:40AM  
09:04AM  
08:15AM  
08:09AM  
07:32AM  
07:04AM  
06:59AM  
04:48AM  
Apr-28-22 09:46PM  
09:06PM  
08:01PM  
10:53AM  
08:40AM  
Apr-27-22 12:00PM  
Apr-26-22 10:37AM  
06:57AM  
Apr-25-22 06:00PM  
10:01AM  
Apr-22-22 03:00PM  
Apr-21-22 05:45PM  
10:13AM  
05:55AM  
Apr-20-22 05:50PM  
12:54PM  
09:17AM  
Apr-18-22 05:25PM  
11:30AM  
10:39AM  
09:32AM  
08:49AM  
Apr-14-22 05:45PM  
05:22PM  
04:42PM  
04:30PM  
09:01AM  
06:30AM  
Apr-12-22 02:57PM  
06:31AM  
Apr-11-22 05:50PM  
03:07PM  
01:51PM  
11:15AM  
09:33AM  
06:59AM  
Apr-08-22 03:17PM  
02:38PM  
11:32AM  
11:07AM  
07:25AM  
Apr-07-22 02:19PM  
01:23PM  
Apr-06-22 12:17PM  
12:08PM  
09:21AM  
05:52AM  
Apr-05-22 05:45PM  
01:40PM  
12:26PM  
12:08PM  
11:11AM  
10:33AM  
10:07AM  
08:58AM  
06:55AM  
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mily ElizabethEVP, Strategy & BDApr 01Option Exercise0.006,347012,481Apr 04 06:13 PM
Caforio GiovanniBoard Chair and CEOMar 21Sale71.5225,0001,788,000581,524Mar 23 07:43 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 16Option Exercise57.0047,3052,696,61293,613Mar 18 05:50 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 16Sale69.2574,5595,162,97346,308Mar 18 05:50 PM
Santiago Karen MurphySVP & ControllerMar 14Sale69.196,577455,09616,704Mar 16 07:32 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 14Sale69.2029,5322,043,52641,966Mar 16 07:32 PM
Caforio GiovanniBoard Chair and CEOMar 10Option Exercise0.00239,5010653,392Mar 14 09:20 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0060,2730388,747Mar 14 09:20 PM
Elkins David VEVP, Chief Financial OfficerMar 10Option Exercise0.0016,0670134,133Mar 14 09:18 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0051,715081,649Mar 14 09:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0035,686078,829Mar 14 09:17 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 10Option Exercise0.0015,247081,213Mar 14 09:16 PM
Santiago Karen MurphySVP & ControllerMar 10Option Exercise0.0011,073024,489Mar 14 09:16 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Mar 10Option Exercise0.009,074018,953Mar 14 09:17 PM
Mily ElizabethEVP, Strategy & BDMar 10Option Exercise0.004,00508,246Mar 14 09:16 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,5770132,034Mar 03 05:33 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 01Option Exercise0.0023,350079,587Mar 03 05:33 PM
Caforio GiovanniBoard Chair and CEOFeb 24Sale67.0030,0002,010,000453,455Feb 28 04:44 PM
VESSEY RUPERTEVP, Research & Early Dev.Feb 04Option Exercise0.003,593057,549Feb 08 06:10 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 16Sale61.9919,2981,196,25231,960Dec 17 05:08 PM
Elkins David VEVP, Chief Financial OfficerDec 02Option Exercise0.008,792088,800Dec 06 06:27 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerDec 02Option Exercise0.002,638039,862Dec 06 06:27 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 02Option Exercise0.008,792055,756Dec 06 06:27 PM
von Autenried PaulEVP, Chief Information OfficerNov 24Sale56.9217,353987,73363,536Nov 24 05:25 PM
von Autenried PaulEVP, Chief Information OfficerNov 23Sale57.4715,418886,07280,889Nov 24 05:25 PM
von Autenried PaulEVP, Chief Information OfficerNov 22Sale57.1718,3631,049,81396,307Nov 24 05:25 PM
Caforio GiovanniBoard Chair and CEOSep 20Sale60.6425,0001,516,000483,980Sep 22 05:19 PM
Elkins David VEVP, Chief Financial OfficerAug 12Option Exercise48.4970,0003,394,300139,699Aug 16 05:51 PM
Elkins David VEVP, Chief Financial OfficerAug 12Sale66.9599,6916,674,49769,699Aug 16 05:51 PM
Powell AnnEVP, Chief Human ResourcesAug 03Sale68.5723,2801,596,31047,613Aug 04 04:46 PM
Caforio GiovanniChairman and CEOAug 02Sale68.5820,0001,371,600508,980Aug 04 04:47 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,4030133,435Aug 03 04:55 PM
VESSEY RUPERTEVP, Research & Early Dev.Jul 30Option Exercise58.49150,9678,830,108187,617Aug 03 04:50 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Jul 30Sale67.902,466167,44113,777Aug 03 04:56 PM
LEUNG SANDRAEVP, General CounselJul 30Sale68.0429,3901,999,696339,967Aug 03 04:54 PM
VESSEY RUPERTEVP, Research & Early Dev.Jul 30Sale68.07158,39310,782,15436,650Aug 03 04:50 PM
von Autenried PaulEVP, Chief Information OfficerJul 30Sale68.0625,0001,701,375114,670Aug 03 04:49 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,069015,045Jul 06 04:38 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,356016,538Jul 06 04:38 PM
Haller Julia ADirectorJun 13Option Exercise0.00902010,670Jun 14 06:56 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.00902012,501Jun 14 06:56 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,154010,223Jun 04 04:36 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94909,768Jun 04 04:35 PM